ELAC2 and prostate cancer: Survival data revealed that higher numbers of A537T‐TRAMP and KO‐TRAMP mice could not survive by 30 weeks of age and beyond 30 weeks a greater number of these mice die as a consequence of their tumours compared with the WT‐TRAMP mice (Fig 1G), indicating that the Elac2 A537T variant can predispose and exacerbate prostate cancer.